ADARx Pharmaceuticals Raises $46M in Series B-1 Financing
- ADARx Pharmaceuticals, a San Diego, CA-based clinical stage biotechnology company developing RNA-targeting therapeutics, raised $46M in Series B-1 funding
- The round was led by Ascenta Capital with participation from OrbiMed Advisors, SR One Capital Management, Lilly Asia Ventures, and Sirona Capital
- In conjunction with this financing, Dr. Lorence Kim of Ascenta Capital has joined the Company’s Board of Directors
- The company intends to use the funds to advance its proprietary RNA targeting platform
- Led by CEO and President Dr. Zhen Li, ADARx is a clinical stage biotechnology company
- The company is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing
